Pesquisar
Caribou Biosciences Inc
CRBUAdicionar à lista de desejos
1.460USD
-0.050-3.31%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
141.55MValor de mercado
PerdaP/L TTM
Mais detalhes de Caribou Biosciences Inc Empresa
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Informações de Caribou Biosciences Inc
Código da empresaCRBU
Nome da EmpresaCaribou Biosciences Inc
Data de listagemJul 23, 2021
CEOHaurwitz (Rachel E)
Número de funcionários147
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 23
Endereço2929 7Th Street, Ste 120
CidadeBERKELEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94710
Telefone15109826030
Sitehttps://www.cariboubio.com/
Código da empresaCRBU
Data de listagemJul 23, 2021
CEOHaurwitz (Rachel E)
Executivos da empresa Caribou Biosciences Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
391.94K
-6.98%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
-316.82%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Caribou Biosciences Inc?
Os cinco principais acionistas de Caribou Biosciences Inc são: Ms. Barbara G. McClung, J.D.
Quantas instituições possuem ações da Caribou Biosciences Inc (CRBU)?
Em 2026Q1, 337 instituições possuíam ações da Caribou Biosciences Inc, com valor de mercado aproximado de 35.96M, representando 36.25% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -24026667.00.